

IFN- β treatment. More studies are warranted to evaluate the possible relationship between the drug and this severe complication.

Funding

Authors do not receive any funding for this paper.

Conflict of interest

Authors do not have any conflicts of interest to disclose associated with this publication.

References

- Nikfar S, Rahimi R, Abdollahi M. A meta-analysis of the efficacy and tolerability of interferon-B in multiple sclerosis overall and by drug and disease type. *Clin Ther.* 2010;32.
- Abdolvahab MH, Mofrad MRK, Schellekens H. Interferon beta: from molecular level to therapeutic effects. *Int Rev Cell Mol Biol.* 2016;326:346–72.
- Zettl U, Hecker M, Aktas O, Wagner T, Rommer P. Interferon B-1a and B-1b for patients with multiple sclerosis: updates to current knowledge. *Expert Rev Clin Immunol.* 2018;14: 137–53.
- Phanthanawiboon S, Limkittikul K, Sakai Y, Takakura N, Saijo M, Kurosu T. Acute systemic infection with dengue virus leads to vascular leakage and death through tumor necrosis factor- α and Tie2/angiopoietin signaling in mice lacking type I and II interferon receptors. *PLOS ONE.* 2016;11.
- Zulfiqar M, Qeadan F, Ikram A, Farooqui M, Richardson SP, Calder CS, et al. Intracerebral haemorrhage in multiple sclerosis: a retrospective cohort study. *J Stroke Cerebrovasc Dis.* 2019;28:267–75.
- Niederwieser G, Bonelli RM, Kammerhuber F, Reisecker F, Kölltringer P. Intracerebral haemorrhage under interferon-beta therapy. *Eur J Neurol.* 2001;8:363–4.
- Shahmohammadi S, Mohammadianinejad SE, Sahraian MA, Moghadasi AN. Intracerebral hemorrhage in a patient with multiple sclerosis receiving interferon beta-1a. *Arch Neurosci.* 2017;4.
- Ben-Amor T, Trochanov A, Fischer T. Cumulative review of thrombotic microangiopathy thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome reports with subcutaneous interferon β -1a. *Adv Ther.* 2015;32:445–54.
- Rot U, Ledinek AH. Interferons beta have vasoconstrictive and procoagulant effects: a woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis. *Clin Neurol Neurosurg.* 2013;115:S79–81.
- Gaetani L, Menduno PS, Cometa F, Di Gregorio M, Sarchielli P, Cagini C. Retinopathy during interferon-B treatment of multiple sclerosis: case report and review of the literature. *J Neurol.* 2016;263:422–7.
- Pakulski LA, Di Marco LM. Severe vaginal bleeding associated with recombinant interferon beta-1B. *Ann Pharmacother.* 1997;31:50–2.
- Sternberg Z, Leung C, Stemberg D, Yu J, Hojnacki D. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis. *Cardiovasc Ther.* 2014;32:33–9.
- Hong Y, Tang H, Ma M, Chen N, Xie X, He L. Multiple sclerosis and stroke: a systematic review and meta-analysis. *BMC Neurol.* 2019;19:139.

A. Sánchez-Soblechero*, J.P. Cuello, M.L. Martínez Ginés, A. Lozano Ros, F. Romero Delgado, C. De Andrés, H. Goicochea Briceño, J.M. García Domínguez
Department of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

* Corresponding author.

E-mail address: antonio.sanchez.s@hotmail.com (A. Sánchez-Soblechero).

<https://doi.org/10.1016/j.nrl.2021.02.002>
0213-4853/

© 2021 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Reduction of photoparoxysmal response from patients with drug-resistant photosensitive epilepsy by using Z1 filters



Reducción de la respuesta fotoparoxística en pacientes con epilepsia fotosensible farmacorresistente mediante el uso de filtros Z1

Dear Editor,

Reflex epilepsy is characterized by seizures triggered by a specific stimulus. Photosensitive epilepsy (PSE) has seizures provoked by photic stimuli. PSE is the most common form of reflex epilepsy and affects 2–5% of patients with epilepsy. The main feature is photosensitivity, which is an abnormal

paroxysmal electrical reaction in the brain induced by strobe lights. The photoparoxysmal response (PPR) is the appearance of epileptiform activity induced by intermittent photic stimulation (IPS).^{1,2}

Capovilla G et al, have demonstrated that Z1-filter, was more effective than four other colored types of lenses in reducing the response to IPS in PSE patients.³ These results were confirmed in a multicenter study, the use of Z1 filters abolished PPR in 75.9% and a 17.9% of PPR attenuation, evaluated by increased latency between the stimulus and the appearance of PPR, reduced duration of PPR, disappearance of clinical manifestations, or change to a less severe type according to Waltz's classification in 17.9% from patients.^{4,5}

It has been previously described that 30% of patients with epilepsy have no control of their seizures, despite the use of 2 or more correctly used AEDs, considering this condition as Drug Resistant Epilepsy (DRE). Valproic acid can control photosensitivity in about 40% of cases. There are no studies




Figure 1 (A) PPR response using Waltz types grouped by filter use (percentage of patients), PPR distribution: (B) Mean and SD, (C) change of the PPR response before and after filter use.

focusing on patients with PSE who are refractory to Valproic Acid. We selected from our database, those patients who had PSE, and continued with seizures despite the use of Valproic Acid in doses of at least 1500 mg/day or higher and a new AED.⁶⁻⁹ Most of patients ($n:9$), have shown plasma levels of Valproic Acid were within the therapeutic range. Nevertheless, in the rest of patients ($n:6$) these levels could not be obtained. In all of studied population, Valproic Acid dosis was tolerated without toxic effects. The correlation between plasma levels of Valproic Acid and PPR wasn't studied. None of the patients received AEDs or other drugs that were hepatic inducers.

The aim of this study was to assess whether the use of Z1 filters can reduce PPR in patients with drug-resistant PSE.

Prospective study to analyze the role of Z1 filters in the PPR from patients with drug-resistant PSE was performed. It was approved by the Ethics Committee of the Hospital Britanico. All patients signed an informed consent form. Patients with PSE, who had seizures despite

being medicated with valproic acid at a minimum dose of 1500 mg and at least one of the following AEDs (levetiracetam: 1000–3000 mg/day, lacosamide 200–400 mg/day and topiramate 200–400 mg/day). For each patient, the maximum tolerated dose without adverse effects was used. were included.

Before performing the EEG, a complete ophthalmological examination was performed on all patients. An EEG was performed in a twilight room with 32-channel equipment (Neurovirtual®). Longitudinal, transversal and reference assemblies were used, according to the International 10/20 System. After 20 min of recording, the IPS was performed with a photo-stimulator placed 30 cm from the patient's face. Each stimulation lasted 1 ms for 5 s at 30-s intervals. Frequencies between 3 and 50 Hz were used. 3 EEG recording with Intermittent Photic Stimulation.

Identical IPS protocol was implemented after the application of the Z.1 filter (Zeiss™) in front of the patient's eyes. PPR was evaluated using the Scale described by Waltz patients,¹⁰ which gives a score from 1 to 4 according to the severity of the response to IPS.

We included 15 patients with PSE. Mean age was 30.3 ± 12.8 years. 53.4% were female. PPR without the use of Z.1 filter showed that the population in this study presented PPR in the following distribution: Type 4: 20% ($n:3$); Type 3: 46.6% ($n:7$); Type 2: 20% ($n:3$); Type 1: 13.4% ($n:2$); Type 1 (Fig. 1A). Our findings showed a significant decrease in PPR severity after the use of Filters Zeiss F.1 filters (0.4 ± 0.2 vs. 2.7 ± 0.9 ; $p < 0.001$) (Fig. 1B). With the use of Zeiss F.1 filters, in more than half of the patients (60%) PPR was abolished (Fig. 1C). Type 1 were 6 patients and with PPR Abolition, 9 patients.

In our study the Z1 Filters were effective in reducing photosensitivity in PSE patients treated with valproic acid and second or third generation AED.

To our knowledge, there are no studies on the reduction of PPR with the use of Z1 filters only in patients with valproic acid associated with a third generation AED.

To avoid photosensitivity, different strategies can be adopted.¹¹ For example, avoiding places where this type of light stimuli are more frequent, treatment with AEDs or the use of special filters.⁵ We agree that the Z1 filters are effective, even in patients receiving pharmacological treatment with 2 AEDs.

References

1. Koepp MJ, Caciagli L, Pressler RM, Lehnertz K, Beniczky S. Reflex seizures, traits, and epilepsies: from physiology to pathology. *Lancet Neurol.* 2016;15:92–105, [http://dx.doi.org/10.1016/S1474-4422\(15\)00219-7](http://dx.doi.org/10.1016/S1474-4422(15)00219-7).
2. Quirk JA, Fish DR, Smith SJ, Sander JW, Shorvon SD, Allen PJ. Incidence of photosensitive epilepsy: a prospective national study. *Electroencephalogr Clin Neurophysiol.* 1995;95:260–7, [http://dx.doi.org/10.1016/0013-4694\(95\)00118-i](http://dx.doi.org/10.1016/0013-4694(95)00118-i).
3. Shervonne P, Szaflarski JP. Photosensitivity in generalized epilepsies. Targeted review. *Epilepsy Behav.* 2017;68:225–33, <http://dx.doi.org/10.1016/j.yebeh.2016.10.040>.
4. Capovilla G, Beccaria F, Romeo A, Veggiotti P, Canger R, Paladin F. Effectiveness of a particular blue lens on photoparoxysmal response in photosensitive epileptic patients. *Ital J Neurol Sci.* 1999;20:161–6, <http://dx.doi.org/10.1007/s100720050026>.

5. Capovilla G, Gambardella A, Rubboli G, et al. Suppressive efficacy by a commercially available blue lens on PPR in 610 photosensitive epilepsy patients. *Epilepsia*. 2006;47:529–33.
6. Harding GF, Edson A, Jeavons PM. Persistence of photosensitivity. *Epilepsia*. 1997;38:663–9, <http://dx.doi.org/10.1111/j.1528-1167.2006.00463.x>.
7. Rimmer EM, Milligan NM, Richens A. A comparison of the acute effect of single doses of vigabatrin and sodium valproate on photosensitivity in epileptic patients. *Epilepsy Res*. 1987;1:339–46, [http://dx.doi.org/10.1016/0920-1211\(87\)90058-1](http://dx.doi.org/10.1016/0920-1211(87)90058-1).
8. Striano P, Coppola A, Pezzella M, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. *Neurology*. 2007;17:250–4, <http://dx.doi.org/10.1212/01.wnl.0000265222.24102.db>.
9. Covanis A. Photosensitivity in idiopathic generalized epilepsies. *Epilepsia*. 2005;46(Suppl. 9):67–72, <http://dx.doi.org/10.1111/j.1528-1167.2005.00315.x>.
10. Waltz S, Christen HJ, Doose H. The different patterns of the photoparoxysmal response—a genetic study. *Electroencephalogr Clin Neurophysiol*. 1992;83:138–45, [http://dx.doi.org/10.1016/0013-4694\(92\)90027-f](http://dx.doi.org/10.1016/0013-4694(92)90027-f).
11. Verrotti A, Beccaria F, Fiori F, Montagnini A, Capovilla G. Photosensitivity: epidemiology, genetics, clinical

manifestations, assessment, and management. *Epileptic Disord*. 2012;14:349–62, <http://dx.doi.org/10.1684/epd.2012.0539>.

O.A. Martinez^{a,*}, L. Lagos^b, G. Ernst^c, R. Ebner^b

^a *Neurology Department, Hospital Británico de Buenos Aires, Argentina*

^b *Ophthalmology Department, Hospital Británico de Buenos Aires, Argentina*

^c *Scientific Advisory Committee, Hospital Británico de Buenos Aires, Argentina*

* Corresponding author.

E-mail address: omartinez@hbritanico.com.ar (O.A. Martinez).

<https://doi.org/10.1016/j.nrl.2020.11.011>

0213-4853/

© 2020 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).